Skip to main content
Equibles
ELTP logo

ELTP · Elite Pharmaceuticals Inc /Nv/

Track ELTP — free

Use ELTP with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ELTP

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.29 +0.00 (+0.31%) At close · Aug 28
Rebalance outlook locked
Market Cap
$312.26M
Shares
1.08B

Elite Pharmaceuticals Inc Earnings Call Transcripts

Quarterly earnings calls for Elite Pharmaceuticals Inc (ELTP), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲8.7% $7.67M $305,883 '23 Q1 22-08-15 ▲0.3% $8.59M $1.52M '23 Q2 22-11-15 ▲3.1% $9.25M $2.97M '23 Q3 23-02-14 ▲12.7% $8.65M −$1.23M '23 Q4 23-06-29 ▲17% $8.98M $1.14M '24 Q1 23-08-14 ▲64.9% $14.16M $14.93M '24 Q2 23-11-14 ▲68% $15.54M $706,354 '24 Q3 24-02-14 ▲109.4% $18.80M $615,773 '25 Q1 24-07-01 ▲33.4% $18.88M −$11.04M '25 Q2 24-11-14 ▼7.6% $14.36M −$10.89M '25 Q3 25-02-13 ▲78.3% $32.00M $17.00M '25 Q4 25-06-30 ▲113.9% $40.21M −$5.88M '26 Q1 25-08-14 ▲92.4% $36.32M $13.70M '26 Q2 25-12-31 ▲119.9% $31.59M $18.59M '26 Q3 26-02-18 ▲27.4% $40.75M $18.46M '26 Q4 26-06-30 LATEST ▼19.5% $32.36M $5.91M '27 Q1 26-08-14
Earnings call
FY27 · Q1
2026-08-14
Elite Pharmaceuticals Inc (ELTP) Q1 2027 Earnings Call
Revenue
$32.36M
▼ 19.5% YoY
Diluted EPS
$0.01
Gross margin
41.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q4
2026-06-30
Elite Pharmaceuticals Inc (ELTP) Q4 2026 Earnings Call
Revenue
$40.75M*
▲ 27.4% YoY
Gross margin
51.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Conference
Investor event
2026-03-31
Elite Pharmaceuticals Inc (ELTP) March 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q3
2026-02-18
Elite Pharmaceuticals Inc (ELTP) Q3 2026 Earnings Call
Revenue
$31.59M
▲ 119.9% YoY
Diluted EPS
$0.01
Gross margin
41.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q2
2025-12-31
Elite Pharmaceuticals Inc (ELTP) Q2 2026 Earnings Call Transcript
Confident tone Revenue growth and milestones M&A and NASDAQ listing exploration Balance sheet and working capital
Revenue
$36.32M
▲ 92.4% YoY
Diluted EPS
$0.01
Gross margin
38.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2025-08-14
Elite Pharmaceuticals Inc (ELTP) Q1 2026 Earnings Call
Revenue
$40.21M
▲ 113.9% YoY
Diluted EPS
$-0.01
Gross margin
67.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2025-06-30
Elite Pharmaceuticals Inc (ELTP) Q4 2025 Earnings Call Transcript
Confident tone Revenue Growth DEA Quota Lisdexamphetamine / Generic Vyvanse
Revenue
$32.00M*
▲ 78.3% YoY
Gross margin
54.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-02-13
Elite Pharmaceuticals Inc (ELTP) Q3 2025 Earnings Call
Revenue
$14.36M
▼ 7.6% YoY
Diluted EPS
$-0.01
Gross margin
42.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2024-11-14
Elite Pharmaceuticals Inc (ELTP) Q2 2025 Earnings Call
Revenue
$18.88M
▲ 33.4% YoY
Diluted EPS
$-0.01
▼ 200% YoY
Gross margin
43.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2024-07-01
Elite Pharmaceuticals Inc (ELTP) Q1 2025 Earnings Call
Revenue
$18.80M
▲ 109.4% YoY
Diluted EPS
$0.00
Gross margin
45.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q3
2024-02-14
Elite Pharmaceuticals Inc (ELTP) Q3 2024 Earnings Call
Revenue
$15.54M
▲ 68% YoY
Diluted EPS
$0.00
Gross margin
45.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2023-11-14
Elite Pharmaceuticals Inc (ELTP) Q2 2024 Earnings Call
Revenue
$14.16M
▲ 64.9% YoY
Diluted EPS
$0.01
Gross margin
45.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2023-08-14
Elite Pharmaceuticals Inc (ELTP) Q1 2024 Earnings Call
Revenue
$8.98M
▲ 17% YoY
Diluted EPS
$0.00
Gross margin
52.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-06-29
Elite Pharmaceuticals Inc (ELTP) Q4 2023 Earnings Call
Revenue
$8.65M*
▲ 12.7% YoY
Gross margin
44.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-02-14
Elite Pharmaceuticals Inc (ELTP) Q3 2023 Earnings Call
Revenue
$9.25M
▲ 3.1% YoY
Diluted EPS
$0.00
Gross margin
53.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2022-11-15
Elite Pharmaceuticals Inc (ELTP) Q2 2023 Earnings Call
Revenue
$8.59M
▲ 0.3% YoY
Diluted EPS
$0.00
Gross margin
44.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2022-08-15
Elite Pharmaceuticals Inc (ELTP) Q1 2023 Earnings Call
Revenue
$7.67M
▲ 8.7% YoY
Diluted EPS
$0.00
Gross margin
52.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-06-29
Elite Pharmaceuticals Inc (ELTP) Q4 2022 Earnings Call
Revenue
$7.67M*
▲ 74.5% YoY
Gross margin
45.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-02-15
Elite Pharmaceuticals Inc (ELTP) Q3 2022 Earnings Call
Revenue
$8.97M
▲ 48.4% YoY
Diluted EPS
$0.00
Gross margin
44.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2021-11-15
Elite Pharmaceuticals Inc (ELTP) Q2 2022 Earnings Call
Revenue
$8.56M
▲ 15.7% YoY
Diluted EPS
$0.00
Gross margin
44.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2021-08-16
Elite Pharmaceuticals Inc (ELTP) Q1 2022 Earnings Call
Revenue
$7.06M
▼ 6.4% YoY
Diluted EPS
$0.00
Gross margin
50.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-06-14
Elite Pharmaceuticals Inc (ELTP) Q4 2021 Earnings Call
Revenue
$4.40M*
▼ 11.1% YoY
Gross margin
42.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-02-16
Elite Pharmaceuticals Inc (ELTP) Q3 2021 Earnings Call
Revenue
$6.05M
▲ 19.6% YoY
Diluted EPS
$0.00
Gross margin
56.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2020-11-16
Elite Pharmaceuticals Inc (ELTP) Q2 2021 Earnings Call
Revenue
$7.40M
▲ 59.7% YoY
Diluted EPS
$0.00
Gross margin
48.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2020-08-17
Elite Pharmaceuticals Inc (ELTP) Q1 2021 Earnings Call
Revenue
$7.54M
▲ 124.4% YoY
Diluted EPS
$0.00
Gross margin
39.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2020-06-29
Elite Pharmaceuticals Inc (ELTP) Q4 2020 Earnings Call
Revenue
$4.95M*
▲ 268% YoY
Gross margin
49.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-02-10
Elite Pharmaceuticals Inc (ELTP) Q3 2020 Earnings Call
Revenue
$5.06M
▲ 87.6% YoY
Diluted EPS
$0.00
Gross margin
57.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–27 of 27 earnings calls
Key facts CIK 1053369 CUSIP 28659T200 13F (30d) 1 filings 1 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)